TTS is also measured in decibels.In addition to hearing loss, other external symptoms of an acoustic trauma can be:

Tinnitus
Otalgia
Hyperacusis
Dizziness or vertigo; in the case of vestibular damages, in the inner-ear

Tinnitus
Tinnitus is described as hearing a sound when an external sound is not present. Noise-induced hearing loss can cause high-pitched tinnitus. An estimated 50 million Americans have some degree of tinnitus in one or both ears; 16 million of them have symptoms serious enough for them to see a doctor or hearing specialist. As many as 2 million become so debilitated by the unrelenting ringing, hissing, chirping, clicking, whooshing or screeching, that they cannot carry out normal daily activities.Tinnitus is the largest single category for disability claims in the military, with hearing loss a close second. The third largest category is post-traumatic stress disorder, which itself may be accompanied by tinnitus and may exacerbate it. Quality of life
NIHL has implications on quality of life that extend beyond related symptoms and the ability to hear. The annual disability-adjusted life years (DALYs) were estimated for noise-exposed U.S. workers. [20]  DALYs represent the number of healthy years lost due to a disease or other health condition. They were defined by the 2013 Global Burden of Disease (GBD) Study. The DALYs calculation accounts for life limitations experienced because of hearing loss as a lost portion of a healthy year of life. So the results indicate the number of healthy years lost by a group of people over a specific time period.
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion. Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is "tissue agnostic"). Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.Phase II clinical trials evaluating the drug for efficacy and safety in treating several types of solid tumors are ongoing.Larotrectinib was approved for medical use in the European Union in September 2019. It was approved for medical use in Australia in August 2020. References
External links
"Larotrectinib". Drug Information Portal. U.S. National Library of Medicine. "Larotrectinib sulfate". National Cancer Institute. "Larotrectinib sulfate". NCI Dictionary of Cancer Terms. National Cancer Institute.